drugset / Trial / NCT02979977
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Phase 2
Completed
50 enrolled
Yale University
Boehringer Ingelheim · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm Phase II study for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who are previously treated with a platinum based regimen or with an immune checkpoint inhibitor. The primary objective is to evaluate the efficacy of the combination of cetuximab and afatinib.
Timeline
- Start
- 2017-03-24
- Primary completion
- 2025-01-18
- Completion
- 2026-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 30 mg | Oral |
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |